tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Nevro Crop (NVRO), Horizon Therapeutics (HZNP) and Jazz Pharmaceuticals (JAZZ)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nevro Crop (NVROResearch Report), Horizon Therapeutics (HZNPResearch Report) and Jazz Pharmaceuticals (JAZZResearch Report).

Nevro Crop (NVRO)

In a report released today, Cecilia Furlong from Morgan Stanley maintained a Hold rating on Nevro Crop, with a price target of $54.00. The company’s shares closed last Thursday at $45.28, close to its 52-week low of $39.41.

According to TipRanks.com, Furlong is a 5-star analyst with an average return of 19.9% and a 50.7% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Bausch + Lomb Corporation, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Nevro Crop is a Hold with an average price target of $62.00, implying a 34.3% upside from current levels. In a report issued on July 20, Truist Financial also maintained a Hold rating on the stock with a $45.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Horizon Therapeutics (HZNP)

In a report released today, Michael Ulz from Morgan Stanley maintained a Buy rating on Horizon Therapeutics, with a price target of $90.00. The company’s shares closed last Thursday at $67.26, close to its 52-week low of $60.76.

According to TipRanks.com, Ulz is a 1-star analyst with an average return of -1.2% and a 38.9% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Blueprint Medicines, and Fate Therapeutics.

Horizon Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $126.64, representing an 84.0% upside. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $138.00 price target.

Jazz Pharmaceuticals (JAZZ)

SVB Securities analyst Marc Goodman maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $210.00. The company’s shares closed last Thursday at $153.02.

According to TipRanks.com, Goodman is a 1-star analyst with an average return of -0.4% and a 43.4% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Opthea Limited Sponsored ADR, and Amylyx Pharmaceuticals Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $205.08 average price target, representing a 32.7% upside. In a report released today, BMO Capital also maintained a Buy rating on the stock with a $188.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NVRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More